Compare ENSG & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENSG | NUVL |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 9.8B |
| IPO Year | 2007 | 2021 |
| Metric | ENSG | NUVL |
|---|---|---|
| Price | $147.23 | $123.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $202.60 | $134.75 |
| AVG Volume (30 Days) | 640.3K | ★ 2.7M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.14% | N/A |
| EPS Growth | ★ 14.06 | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | ★ $5,057,841,000.00 | N/A |
| Revenue This Year | $17.07 | N/A |
| Revenue Next Year | $9.49 | $1,239.49 |
| P/E Ratio | $90.81 | ★ N/A |
| Revenue Growth | ★ 18.72 | N/A |
| 52 Week Low | $134.80 | $71.14 |
| 52 Week High | $218.00 | $123.62 |
| Indicator | ENSG | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 23.21 | 66.62 |
| Support Level | N/A | $97.71 |
| Resistance Level | $181.79 | N/A |
| Average True Range (ATR) | 5.97 | 4.24 |
| MACD | -1.48 | 2.74 |
| Stochastic Oscillator | 20.30 | 99.49 |
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.